This 45-minute podcast features the expertise of a pathologist and an oncologist highlighting important and practice-changing developments related to the use of Ki67 biomarker testing in patients with HR-positive/HER2-negative early breast cancer, such as new clinical data with immediate implications for patient care. Case-based, and with expert perspectives ... Show More
Mar 2022
Robert Dreicer, MD, MS, MACP, FASCO - Decisions and Dilemmas in Prostate Cancer Management: Building on Progress to Advance Personalized Care Through Candid Conversations and Expert Clinical Consults
Go online to PeerView.com/GZF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Clinicians who treat patients with prostate cancer have new opportunities to improve outcomes across a variety of settings, but the rapid expansion ... Show More
1h 21m
May 2022
John J. Russell, MD - Cancer Control Through Early Blood-Based Detection: Perspectives on Integrating Innovative Multicancer Early Detection Tests in the Primary Care Setting
Go online to PeerView.com/MBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Blood-based cancer screening has the potential to revolutionize conventional approaches to early cancer detection—are you current on the recent sci ... Show More
29m 36s
Oct 2021
Melissa L. Johnson, MD - Harnessing the Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLC
Go online to PeerView.com/ANP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for NSCLC with and without genomic alterations is continuously growing, and novel HER2-, HER3-, and TROP2-targeting antibody– ... Show More
59m 7s
May 2022
Bhavana Pothuri, MD, MS - Expanding the Benefits and Refining the Role of Immune Checkpoint Inhibitors in the Treatment of Recurrent and Advanced Endometrial Cancer
Go online to PeerView.com/KWF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in oncology discusses the role of immune checkpoint inhibitors in the care of patients with recurrent and advanced endo ... Show More
28m 20s
May 2022
Bradley J. Monk, MD, FACS, FACOG - When Are PARP Inhibitors the Best Choice for Patients With Ovarian Cancer? Personalizing Therapeutic Selection Across the Disease Continuum
Go online to PeerView.com/YWA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you optimizing the care of your patients with ovarian cancer with poly (ADP-ribose) polymerase (PARP) inhibitors and novel therapies such as tu ... Show More
56m 25s
Apr 2022
Pasi A. Jänne, MD, PhD - Addressing Key Targets in Advanced NSCLC: Evaluating the Latest Evidence and Clinical Opportunities for HER2-, HER3-, and TROP2-Targeted Therapies
Go online to PeerView.com/ZGP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for non–small cell lung cancer (NSCLC) with and without genomic alterations continues to expand, and novel HER2-, HER3-, and ... Show More
57m 55s
Mar 2022
Richard S. Finn, MD - Mapping the Optimal Treatment Route in HCC: Identifying Best Practices in an Expanding Therapeutic Landscape
Go online to PeerView.com/VMC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit.Are you prepared to implement the latest recommended therapies into your hepatocellular carcinoma (HCC) practice? With several available treatment m ... Show More
1h 35m
Aug 2022
Jason Westin, MD, MS, FACP - Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR T-Cell Therapy in Community Practice
Go online to PeerView.com/NMF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chimeric antigen receptor T-cell (CAR T) therapy, a validated novel therapeutic strategy in leukemic and lymphoid malignancies, continues to provid ... Show More
1h 30m
Aug 2022
Jacob Sands, MD - Assessing the Impact of Therapeutic Advances in SCLC: Instilling New Hope and Moving in Leaps and Bounds Toward Better Outcomes
Go online to PeerView.com/VDU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decad ... Show More
1h 24m